|

Surufatinib, gemcitabine, nab-paclitaxel Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1
  • Fudan University1

Indications

  • Cancer2
  • Pancreatic Cancer, Adult1
  • Pancreatic Cancer Metastatic1

Other2 trials

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase 2
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.